Citations

Showing 10 of 108119 citations.

Pembrolizumab Achieves a Complete Response in an NF-1 Mutated, PD-L1 Positive Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Benchmarks
Larson, Kristian , Russ, Atlantis Dawn, Arif‐Tiwari, Hina , Mahadevan, Daruka , Elliott, Alex, Bhattacharyya, A. K. , Elliott, Alex, Babiker, Hani M.

Mayo Clinic

Journal of Immunotherapy | January 12, 2022 | Volume: 45 | Issue: 4 | Pages: 222-226

10.1097/cji.0000000000000410 | PMID 35020691 Get It

Malignant peripheral nerve sheath tumors (MPNSTs) represent a rare subtype of neural crest cell-derived soft tissue sarcomas (STS). Standard of care therapy comprises surgical resection followed by adjuvant radiation, and most clinical studies have demonstrated finite survival benefit of radiation and chemotherapy. In metastatic disease, palliative chemotherapy provides very limited efficacy. We report a 60-year-old male patient with a primary para vertebral tumor at T7–T8 with lung metastases who recurred after surgical resection and later progressed on epirubicin plus ifosfamide. He was an international patient and referred to the phase 1 clinic. Molecular profiling and immunohistochemistry of the tumor revealed a PD-L1 expression of 70% (2+) and pathogenic genetic alterations by next-generation sequencing in ARID1A, CDKN2A, KMT2A, NF1, and TP53. Immune checkpoint therapy (ICT) with pembrolizumab was commenced, and interval computed tomography revealed a complete remission by cycle 6. Randomized clinical trials illustrate that ICTs such as anti-PD-1 and anti-CTLA4 monoclonal antibodies in STS cohorts display low or modest response rates by variable PD-L1 expression. This and 3 other case reports of disparate PD-L1 expression demonstrate complete responses in PD-L1 positive MPNSTs treated with ICT. These case reports necessitate further study of ICT in neural crest cell subtype of STS.
Systemic manifestations and symptom burden of facioscapulohumeral muscular dystrophy in a referral cohort
Kelly, Cecilia R. , Saw, Jacqui‐Lyn , Thapa, Prabin , Mandrekar, Jay , Naddaf, Elie , Naddaf, Elie

Mayo Clinic

Muscle & Nerve | January 12, 2022 | Volume: 65 | Issue: 4 | Pages: 415-421

10.1002/mus.27493 | PMID 35020192 Get It

AbstractIntroduction/AimsThe full spectrum of the clinical phenotype of facioscapulohumeral muscular dystrophy (FSHD), beyond skeletal muscle weakness, remains poorly characterized. In this study, we describe systemic manifestations and symptom burden in a large series of FSHD patients.MethodsWe performed a retrospective chart review of FSHD patients seen at our institution between 2000 and 2017. We reviewed patients' responses to a comprehensive review of symptoms and the results of diagnostic testing for sensorineural hearing loss, cardiac disease, dysphagia, ocular abnormalities, and respiratory insufficiency. We assessed the association between disease manifestations and age of onset, genetic profile, and disease duration.ResultsWe identified 87 patients with FSHD. The most common reported symptoms included pain (71%), difficulty sleeping (41%), headaches (27%), and altered mood (24%). When tested, 7 of 16 (44%) patients had sensorineural hearing loss, 20 of 60 (33%) had cardiac arrhythmias or conduction defects, 17 of 45 (38%) had echocardiogram abnormalities, 12 of 25 (48%) had reduced forced vital capacity, and 4 of 10 (40%) had oropharyngeal dysphagia. However, patients with these abnormalities represented 8%, 23%, 20%, 14%, and 5% of total number of patients, respectively, as uniform screening was lacking. Ocular pathology attributable to FSHD was not detected.DiscussionFSHD demonstrates a broad clinical phenotype. Increased vigilance among neurologists to screen for systemic manifestations of the disease is warranted. More uniform screening and future population‐based studies are needed to compare findings in FSHD patients with the general population.
Editorial Comment: Artificial Intelligence in Mammography—Our New Reality
Khanani, Sadia, Khanani, Sadia

Mayo Clinic

American Journal of Roentgenology | January 12, 2022 | Volume: 219 | Issue: 3 | Pages: 381-381

10.2214/ajr.22.27345 | PMID 35018799 Get It

Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions
Barakat, Benan , Messina, Steve, Nayak, Shreya, Kassa, Roman, Sechi, Elia , Kantarci, Orhun H. , Keegan, B. Mark , Flanagan, E P , Keegan, B Mark , Sechi, Elia , Barakat, Benan , Nayak, Shreya, Flanagan, Eoin P. , Weinshenker, Brian G.

Mayo Clinic

Multiple Sclerosis Journal - Experimental, Translational and Clinical | January 12, 2022 | Volume: 8 | Issue: 1 | Pages: No page available

10.1177/20552173211052159 | PMID 35047187 Get It

Background Elevated intrathecal immunoglobulin G (IgG; oligoclonal bands (OCBs)) or IgG in people with progressive motor impairment due to “critical” demyelinating lesions are of uncertain significance. Objective Compare clinical/radiological features of people with “critical” demyelinating lesion-induced progressive motor impairment with/without elevated intrathecal IgG synthesis. Methods A total of 133 people with progressive motor impairment attributable to “critical” demyelinating lesions (corticospinal tract location, consistent with the progressive motor deficit) were compared regarding clinical and radiological presentation with and without ≥2 unique cerebrospinal fluid (CSF) OCB and/or IgG index ≥0.85. Results Ninety-eight (74%) had CSF-elevated OCB and/or IgG index, higher with increased magnetic resonance imaging-lesion burden. No differences were found with/without CSF abnormalities in sex (46 of 98 female (47%) vs. 22 of 35 (63%), p = 0.11), onset-age (median 49 vs. 50 years, p = 0.5), progression from onset (62 of 98 (63%) vs. 25 of 35 (71%)), progression post-relapse (36 of 98 (37%) vs. 10 of 35 (29%), p = 0.4), and duration between demyelinating disease onset and CSF examination (30 (0–359) vs. 48 (0–323) months p = 0.7). “Critical” lesions were radiologically similar, most commonly cervical spine located (72 of 98 (74%) vs. 19 of 35 (54%), p = 0.18) both with/without CSF abnormalities. Conclusions People with “critical” demyelinating lesion-induced progressive motor impairment typically have elevated intrathecal IgG (OCB and/or IgG) and similar clinical and radiological presentation regardless of CSF findings, therefore representing valid presentations of progressive demyelinating disease.
Five‐year outcomes of transcatheter mitral valve implantation and redo surgery for mitral prosthesis degeneration
Simard, Trevor , Lloyd, James W. , Thaden, Jeremy J. , Guerrero, Mayra , Rihal, Charanjit S. , Eleid, Mackram F. , Lloyd, James , Guerrero, Mayra E , Simard, Trevor , Crestanello, Juan A. , Alkhouli, Mohamad , Rihal, Charanjit S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 12, 2022 | Volume: 99 | Issue: 5 | Pages: 1659-1665

10.1002/ccd.30059 | PMID 35019211 Get It

AbstractBackgroundTranscatheter mitral valve replacement (TMVR) has emerged as a feasible alternative to redo surgical mitral valve replacement (SMVR) in patients with degenerated mitral prostheses, with limited comparative data.MethodsWe compared mid‐term outcomes in patients with degenerated mitral valve prostheses treated with TMVR or redo SMVR. The primary endpoint was survival at 5 years of follow‐up.ResultsFrom 2014 to 2020, 215 patients presented with degenerated mitral valve prostheses. Of whom 86 (40%) were treated with TMVR (75[87%] valve‐in‐valve and 11[13%] valve‐in‐ring), while 129 patients (60%) underwent SMVR. The TMVR cohort was older (p < 0.0001), more symptomatic (p = 0.0003) and had more chronic lung disease (p = 0.02), worse renal function (p = 0.02) and higher right ventricular systolic pressures (p < 0.0001). Thirty‐day mortality was lower with TMVR versus SMVR (2.4% vs. 10.2%, OR4.69 [95% CI 1.25–30.5], p = 0.04) with probability of mortality at 1, 2, and 5 years being 14.7% versus 17.5%, 24.5% versus 20.7%, and 49.9% versus 34.0%, respectively. Mode of prosthesis degeneration, baseline hemodynamics, and valve selection did not appreciably impact outcomes.ConclusionsTMVR for degenerated mitral prostheses is associated with better early survival compared to SMVR despite a greater burden of comorbidities. In contrast, 5 year survival rates appear more favorable with SMVR, which may reflect the lower baseline risk of this population. Clinical, hemodynamic, and echocardiographic follow‐up support the mid‐term durability of TMVR for degenerated mitral prostheses. Further dedicated studies, however, are required to optimize outcomes in this challenging patient cohort and to navigate the choice of approach for each individual patient.
The impact of pulmonary hypertension on outcomes of transcatheter mitral valve replacement in mitral annular calcification
Cajigas, Héctor , Kaptzan, Tatiana, Lewis, Bradley R., El‐Sabbagh, Abdallah, Al‐Hijji, Mohammed , Eleid, Mackram F. , Wang, Dee Dee , Eng, Marvin H. , Kodali, Susheel , Chakravarty, Tarun , O’Hair, Daniel, Jones, Noah, Makkar, Raj , Reisman, Mark, Leon, Martin B. , Rihal, Charanjit S. , Cajigas, Hector R , Eleid, Mackram F , Wang, Dee Dee , Pershad, Ashish , Rihal, Charanjit, Guerrero, Mayra E , Al-Hijji, Mohammed A , Alkhouli, Mohamad , George, Isaac , Pershad, Ashish , O’Neill, William W. , Rihal, Charanjit S. , Guerrero, Mayra

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 12, 2022 | Volume: 99 | Issue: 5 | Pages: 1647-1658

10.1002/ccd.30057 | PMID 35019204 Get It

AbstractObjectivesTo assess the impact of pulmonary hypertension (PH) on outcomes of patients with severe mitral annular calcification (MAC) undergoing transcatheter mitral valve replacement (TMVR).BackgroundPH is associated with poor outcomes after mitral valve surgery. Whether the presence of PH in patients with MAC undergoing (TMVR) is associated with poor outcomes, is unknown.MethodsRetrospective evaluation of 116 patients from 51 centers in 11 countries who underwent TMVR with valve in mitral annular calcification (ViMAC) using balloon‐expandable aortic transcatheter valves (THVs) from September 2012 to March 2017. Pulmonary artery systolic blood pressure (PASP) by echocardiogram was available in 90 patients. The subjects were stratified based on PASP: No PH = PASP ≤35 mmHg (n = 11); mild to moderate PH = PASP 36–49 mmHg (n = 21) and severe PH = PASP ≥50 mmHg (n = 58). Clinical, procedural, and echocardiographic outcomes were assessed.ResultsMean age was 72.7 (±12.8) years, 59 (65.6%) were female, Society of Thoracic Surgeons score was 15.8 + 11.8% and 90.0% where in New York Heart Association (NYHA) class III–IV. There was no significant difference in all‐cause mortality at 30 days (no PH = 27.3%, mild–moderate PH = 19.0%, severe PH = 31.6%; p = 0.55) or at 1 year (no PH = 54.5%, mild–moderate PH = 38.1%, severe PH = 56.1%; p = 0.36). No difference in adverse events, NYHA class or amount of residual mitral regurgitation at 1 year were observed between the groups.ConclusionThis study suggests that the presence of PH in patients with predominantly mitral stenosis with MAC undergoing TMVR does not impact mortality or adverse events. Further studies are needed to fully understand the effect of PH in this group of patients.
Sonographic pulmonary response after tracheal occlusion in fetuses with severe isolated congenital diaphragmatic hernia
Trad, Ayssa Teles Abrão , Czeresnia, Ricardo Mamber , Ruano, Rodrigo , Czeresnia, Ricardo, Narang, Kavita , Ruano, Rodrigo , Ibirogba, Eniola R.

Mayo Clinic

Journal of Clinical Ultrasound | January 12, 2022 | Volume: 50 | Issue: 2 | Pages: 185-190

10.1002/jcu.23121 | PMID 35019149 Get It

AbstractPurposeTo report the longitudinal lung growth and prognosis of fetuses with severe left sided congenital diaphragmatic hernia (CDH) treated with fetoscopic tracheal occlusion (FETO) in a single institution.MethodsFetal lung size (observed‐to‐expected lung area to head circumference [o/e‐LHR]) was measured in seven consecutive fetuses with isolated severe left‐sided CDH who underwent FETO. Fetal lung growth was used to prognosticate survival and need for ECMO.ResultsSeven consecutive fetuses had a FETO procedure in the timeframe of this study. A total of 44 longitudinal ultrasound were performed to evaluate lung development. FETO was performed at GA 28.5 ± 0.5 weeks. Five (71.4%) infants survived to one‐year follow‐up and ECMO was needed in three patients (42.8%). Fetal lung response was observed in all fetuses; mean o/e‐LHR increased from 22.5% ± 1.4 before FETO to 44.4% ± 9.8 before delivery. Infants who survived had a higher percentage of fetal lung growth (21.8%) than those who died (8.25%).ConclusionOur study supports the hypothesis that FETO promotes fetal lung growth in fetuses with severe left‐sided CDH, and the fetal pulmonary response seems to be associated with improved outcomes after the procedure.
Accelerated versus watchful waiting strategy of kidney replacement therapy for acute kidney injury: a systematic review and meta-analysis of randomized clinical trials
Chen, Jui‐Yi , Pan, Heng‐Chih , Hsieh, Chih-Chieh , Hsu, Tsuen‐Wei , Huang, Yun‐Ting , Huang, Tao‐Min , Huang, Chun-Te , Kashani, Kianoush , Kashani, Kianoush B , Chen, Yung‐Ming , Shiao, Chih‐Chung , Wu, Vin‐Cent

Mayo Clinic

Clinical Kidney Journal | January 12, 2022 | Volume: 15 | Issue: 5 | Pages: 974-984

10.1093/ckj/sfac011 | PMID 35498901 Get It

ABSTRACT Background Critically ill patients with severe acute kidney injury (AKI) requiring kidney replacement therapy (KRT) have a grim prognosis. Recently, multiple studies focused on the impact of KRT initiation time [i.e., accelerated versus watchful waiting KRT initiation (WWS-KRT)] on patient outcomes. We aim to review the results of all related clinical trials. Methods In this systematic review, we searched all relevant randomized clinical trials from January 2000 to April 2021. We assessed the impacts of accelerated versus WWS-KRT on KRT dependence, KRT-free days, mortality and adverse events, including hypotension, infection, arrhythmia and bleeding. We rated the certainty of evidence according to Cochrane methods and the GRADE approach. Results A total of 4932 critically ill patients with AKI from 10 randomized clinical trials were included in this analysis. The overall 28-day mortality rate was 38.5%. The 28-day KRT-dependence rate was 13.0%. The overall incident of KRT in the accelerated group was 97.4% and 62.8% in the WWS-KRT group. KRT in the accelerated group started 36.7 h earlier than the WWS-KRT group. The two groups had similar risks of 28-day [pooled log odds ratio (OR) 1.001, P = 0.982] and 90-day (OR 0.999, P = 0.991) mortality rates. The accelerated group had a significantly higher risk of 90-day KRT dependence (OR 1.589, P = 0.007), hypotension (OR 1.687, P &lt; 0.001) and infection (OR 1.38, P = 0.04) compared with the WWS-KRT group. Conclusions This meta-analysis revealed that accelerated KRT leads to a higher probability of 90-day KRT dependence and dialysis-related complications without any impact on mortality rate when compared with WWS-KRT. Therefore, we suggest the WWS-KRT strategy for critically ill patients.
Gender-Inclusive Fellowship Naming and Equity, Diversity, and Inclusion in Radiology: An Analysis of Radiology Department Websites in Canada and the United States
Yan, Tyler D. , Mak, Lauren E. , Carroll, Evelyn F. , Khosa, Faisal , Yong‐Hing, Charlotte J.

Mayo Clinic

Canadian Association of Radiologists Journal | January 12, 2022 | Volume: 73 | Issue: 3 | Pages: 473-477

10.1177/08465371211066104 | PMID 35019762 Get It

Purpose: Transgender and gender non-binary (TGNB) individuals face numerous inequalities in healthcare and there is substantial work to be done in fostering TGNB culturally competent care in radiology. A radiology department’s online presence and use of gender-inclusive language are essential in promoting an environment of equity, diversity, and inclusion (EDI). The naming of radiology fellowships and continuing medical education (CME) courses with terminology such as “Women’s Imaging” indicates a lack of inclusivity to TGNB patients and providers, which could result in suboptimal patient care. Methods: We conducted a cross-sectional analysis of all institutions in Canada and the United States (US) offering training in Breast Imaging, Women’s Imaging, or Breast and Body Imaging. Data was collected from each institution’s radiology department website pertaining to fellowship names, EDI involvement, and CME courses. Results: 8 Canadian and 71 US radiology fellowships were identified. 75% of Canadian and 90% of US fellowships had gender-inclusive names. One (12.5%) Canadian and 29 (41%) US institutions had EDI Committees mentioned on their websites. Among institutions publicly displaying CME courses about breast/body or women’s imaging, gender-inclusive names were used in only 1 (25%) of the Canadian CME courses, compared to 81% of the US institutions. Conclusions: Most institutions in Canada and the US have gender-inclusive names for their radiology fellowships pertaining to breast and body imaging. However, there is much opportunity to and arguably the responsibility for institutions in both countries to increase the impact and visibility of their EDI efforts through creation of department-specific committees and CME courses.